SG10201911221RA - Bicyclic heteroaryl derivatives as cftr potentiators - Google Patents

Bicyclic heteroaryl derivatives as cftr potentiators

Info

Publication number
SG10201911221RA
SG10201911221RA SG10201911221RA SG10201911221RA SG10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA SG 10201911221R A SG10201911221R A SG 10201911221RA
Authority
SG
Singapore
Prior art keywords
bicyclic heteroaryl
heteroaryl derivatives
cftr potentiators
potentiators
cftr
Prior art date
Application number
SG10201911221RA
Other languages
English (en)
Inventor
Joseph Strohbach
David Limburg
John Mathias
Atli Thorarensen
James Mousseau
Rajiah Denny
Christoph Zapf
Ivan Efremov
Original Assignee
Cystic Fibrosis Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found filed Critical Cystic Fibrosis Found
Publication of SG10201911221RA publication Critical patent/SG10201911221RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201911221RA 2016-12-16 2017-12-14 Bicyclic heteroaryl derivatives as cftr potentiators SG10201911221RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
SG10201911221RA true SG10201911221RA (en) 2020-02-27

Family

ID=62557188

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201911076QA SG10201911076QA (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators
SG10201911221RA SG10201911221RA (en) 2016-12-16 2017-12-14 Bicyclic heteroaryl derivatives as cftr potentiators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201911076QA SG10201911076QA (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Country Status (11)

Country Link
US (4) US10131670B2 (pt)
EP (1) EP3554506B1 (pt)
JP (1) JP7150721B2 (pt)
CN (1) CN110300589B (pt)
AU (2) AU2017378324B2 (pt)
BR (1) BR112019012335A2 (pt)
CA (1) CA3046968A1 (pt)
MX (1) MX2019007135A (pt)
RU (1) RU2753056C2 (pt)
SG (2) SG10201911076QA (pt)
WO (1) WO2018112149A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
CN108349995B (zh) 2015-11-25 2021-08-03 吉利德阿波罗公司 吡唑acc抑制剂及其用途
EA201890910A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА
WO2017091602A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
DK3551622T3 (da) 2016-12-09 2020-11-23 Vertex Pharma Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AR118555A1 (es) * 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020250116A1 (en) * 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
EP3999063A1 (en) 2019-07-15 2022-05-25 Novartis AG Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
JP2022544383A (ja) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Cftrモジュレータの結晶形態
BR112023002651A2 (pt) 2020-08-20 2023-04-04 Univ Leland Stanford Junior Métodos de tratamento de doenças respiratórias definidas por hipersecreção de muco
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
KR20130141706A (ko) 2005-12-02 2013-12-26 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에 유용한 치환된 4-아미노-피롤로트리아진 유도체
EP1973917B1 (en) 2005-12-29 2015-06-10 AbbVie Inc. Protein kinase inhibitors
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
HUE028008T2 (en) * 2010-02-05 2016-11-28 Adverio Pharma Gmbh sGC stimulators or sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2915418C (en) 2013-07-02 2022-05-03 Rhizen Pharmaceuticals Sa Novel selective pi3k delta and/or gamma protein kinase inhibitors
UA125400C2 (uk) 2016-11-18 2022-03-02 Цистік Фіброзис Фаундейшн Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)

Also Published As

Publication number Publication date
EP3554506A4 (en) 2020-06-10
US10208053B2 (en) 2019-02-19
SG10201911076QA (en) 2020-01-30
RU2019120990A (ru) 2021-01-18
EP3554506A1 (en) 2019-10-23
CN110300589A (zh) 2019-10-01
AU2021277702A1 (en) 2021-12-23
US10377762B2 (en) 2019-08-13
AU2017378324B2 (en) 2021-09-02
CA3046968A1 (en) 2018-06-21
JP2020502103A (ja) 2020-01-23
MX2019007135A (es) 2019-11-18
CN110300589B (zh) 2023-03-10
US20190330219A1 (en) 2019-10-31
AU2021277702B2 (en) 2023-11-30
US20180170938A1 (en) 2018-06-21
RU2019120990A3 (pt) 2021-01-18
RU2753056C2 (ru) 2021-08-11
US10766904B2 (en) 2020-09-08
US20190016728A1 (en) 2019-01-17
WO2018112149A1 (en) 2018-06-21
EP3554506B1 (en) 2021-04-28
US20190016727A1 (en) 2019-01-17
AU2017378324A1 (en) 2019-06-27
JP7150721B2 (ja) 2022-10-11
US10131670B2 (en) 2018-11-20
BR112019012335A2 (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
SG10201911221RA (en) Bicyclic heteroaryl derivatives as cftr potentiators
IL266668A (en) Pyrrolopyrimidines as cftr enhancers
HRP20182073T1 (hr) Derivati kinoksalina korisni kao modulatori fgfr kinaze
IL246474A0 (en) Heteroaryl substituted nicotinamide compounds
IL253588A0 (en) History of bicyclic quinazolinones
EP3116858A4 (en) Azaspiro derivatives as trpm8 antagonists
EP3323809A4 (en) Bicyclic heterocyclic amide derivative
SG11201805869XA (en) Quinolin-2-one derivatives
EP3253753A4 (en) Ergoline compounds and uses thereof
EP3372601A4 (en) NEW HETEROCYCLIC BICYCLIC COMPOUND
EP3440470A4 (en) SHOCK DETECTOR
EP3352758A4 (en) Deuterated cftr potentiators
ZA201804966B (en) 2-oxindole compounds
EP3434149A4 (en) CHILD BED THAT CAN BE REASSEMBLED
EP3269721A4 (en) Bicyclic pyridine compound
EP3150598A4 (en) Substituted tropane derivatives
IL281175A (en) Bicyclic heteroaryl derivatives
EP3449196A4 (en) VERTICAL CHIP DRYER
PT3319956T (pt) Derivados de oxopiridina substituída
AU2016213V (en) PJ01 Pandorea jasminoides
AU2015902298A0 (en) Anti-fungal potentiators